BioStock interview

Last week, Alzinova AB shared positive topline results from the phase 1b study with our vaccine candidate ALZ-101 against Alzheimer's disease. The full analysis of study data for ALZ-101 is expected to be completed in Q1 2024, and BioStock - Connecting Innovation and Capital has taken the time to talk to our CEO, Kristina Torfgård, to get an insight into our major steps forward.